Pasar al contenido principal

ENTENDIENDO DEL MODO DE ACCION Y LA BIODEGRADACION DE NANOMEDICINAS BASADAS EN NANOPARTICULAS PARA OPTIMIZAR SU APLICACION EN TERAPIAS ANTITUMORALES.

PRE2018-084189

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhancing magnetic hyperthermia at the cell membrane by anchoring 92R-functionalized magnetic nanoparticles to low-endocytic CCR9 surface receptors

  • Egea-Benavente, David
  • Corraliza-Gorjón, Isabel
  • Zanten, Thomas S. van
  • Morales, María Del Puerto
  • Kremer, Leonor
  • Barber, Domingo F.
The data that support the findings of this study are available from the corresponding author upon reasonable request., Magnetic hyperthermia therapy (MHT) is a promising cancer treatment that has demonstrated efficacy in phase I and II clinical trials for glioblastoma and prostate cancer. MHT relies on heat generated by magnetic nanoparticles (MNPs) when exposed to alternating magnetic fields (AMFs). The heat output depends not only on the intrinsic properties of MNPs but also on extrinsic factors such as the extracellular and intracellular environments. Aggregation of MNPs under certain conditions can significantly reduce therapeutic efficiency. To overcome this limitation, we present a strategy to enhance MHT by modulating MNP-cell interactions. We functionalized dimercaptosuccinic acid (DMSA)-coated MNPs with the 92R antibody (DMSA-MNPs@92R), which selectively binds to the low-internalization chemokine receptor CCR9, overexpressed in certain tumors. Exposure of CCR9+ MOLT-4 cells to DMSA-MNPs@92R under AMFs resulted in enhanced tumor cell death. Our approach enables spatially controlled binding, maintaining MNPs in a less-aggregated state and at an optimal distance from the cell membrane to maximize heat generation. Mechanistic analysis confirmed that cytotoxicity is driven by localized hyperthermia at the subcellular level rather than a macroscopic temperature increase. These findings underscore the potential of controlled MNPs-cell interactions to improve in vitro MHT performance and open an interesting avenue for enhancing therapeutic efficacy., D.E.-B. is a predoctoral fellow at the Molecular Biosciences Program of the Universidad Autónoma de Madrid supported by the Spanish Ministry of Science and Innovation through a FPI Contract (PRE2018-084189). This work was supported in part by the Spanish Ministry of Science and Innovation through Grant SAF-2017-82223-R (to D.F.B., funded by MCIN/AEI/10.13039/501100011033 and by the ERDF a way of making Europe), PID2019-105404RB-I00 (to L.K., funded by MCIN/AEI/10.13039/501100011033), PID-2020-112685RB-I00 (to D.F.B., funded by MCIN/AEI/10.13039/501100011033), PID2023-150170OB-I00 (to M.P.M., funded by MCIN/AEI/10.13039/501100011033), and PID-2023-146212OB-I00 (to D.F.B, funded by MCIN/AEI/10.13039/501100011033 and by the ERDF, EU). This work was also supported by the CSIC Grant PIE-202320E096 (to L.K.). T.S.v.Z. acknowledges the Severo Ochoa Program for Centres of Excellence, Grant CEX2023-001286-S funded by MICIU/AEI/10.13039/501100011033. The Centro Nacional de Biotecnología (CNB-CSIC) a Severo Ochoa Center of Excellence (CEX2023-001386-S) funded by MICIU/AEI /10.13039/501100011033. The groups of D.F.B. and M.P.M. are part of the “Nanotechnology in Translational Hyperthermia” Network supported by the Spanish Ministry of Science and Innovation (HIPERNANO, RED2018-102626-T, funded by MCIN/AEI/10.13039/501100011033). This research work was performed in the framework of the Nanomedicine CSIC HUB and the CSIC Cancer HUB., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2023-001286-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2023-001386-S)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Enhancing Magnetic Hyperthermia at the Cell Membrane by Anchoring 92R‐Functionalized Magnetic Nanoparticles to Low‐Endocytic CCR9 Surface Receptors

  • Egea-Benavente, David
  • Corraliza-Gorjón, Isabel
  • Van Zanten, Thomas S.
  • Morales, María del Puerto
  • Kremer, Leonor
  • Barber, Domingo F.
Magnetic hyperthermia therapy (MHT) is a promising cancer treatment that has demonstrated efficacy in phase I and II clinical trials for glioblastoma and prostate cancer. MHT relies on heat generated by magnetic nanoparticles (MNPs) when exposed to alternating magnetic fields (AMFs). The heat output depends not only on the intrinsic properties of MNPs but also on extrinsic factors such as the extracellular and intracellular environments. Aggregation of MNPs under certain conditions can significantly reduce therapeutic efficiency. To overcome this limitation, we present a strategy to enhance MHT by modulating MNP-cell interactions. We functionalized dimercaptosuccinic acid (DMSA)-coated MNPs with the 92R antibody (DMSA–MNPs@92R), which selectively binds to the low-internalization chemokine receptor CCR9, overexpressed in certain tumors. Exposure of CCR9+ MOLT-4 cells to DMSA–MNPs@92R under AMFs resulted in enhanced tumor cell death. Our approach enables spatially controlled binding, maintaining MNPs in a less-aggregated state and at an optimal distance from the cell membrane to maximize heat generation. Mechanistic analysis confirmed that cytotoxicity is driven by localized hyperthermia at the subcellular level rather than a macroscopic temperature increase. These findings underscore the potential of controlled MNPs-cell interactions to improve in vitro MHT performance and open an interesting avenue for enhancing therapeutic efficacy.